Akademik Veri Yönetim Sistemi
8th World Congress of the World Association of Dual Disorders (WADD), Balears, İspanya, 17 - 20 Nisan 2024, ss.140, (Tam Metin Bildiri)
Acamprosate is one of a limited number of therapeutic agents approved for the treatment of alcohol dependence. It is thought that as a result of lasted alcohol consumption lead to alcohol addiction by impair balance of inhbition and excitation in central nervous system. Acamprosate causes to decrease craving in people who suffer from alcohol use disorder by it reduce glutamat activity and increase GABA effect. Most side effects of this drugs are transient and mild to moderate in severity. Not only adverse effects are associated with gastrointestinal system with tend to be seen more common (diarrhea, abdominal pain, nausea, flatulence) but also skin redness and loss of sexual desire may be accepted that among usual side effects. In this case we share parkinsonism symptoms which occured after the two months acamprosate treatment in young adult patient who has no history of neurologic disease. According to Naranjo Criterias patient had scored 6 (probable adverse effect). In our case severe extrapyramidal symptoms had started to decrease on second day, completely disappeared on sixth day which acamprosate discontinued. It is observed that acamprosate led to this situation may decline dopamine levels in the ventral tegmental area. We hope that our case will have added in literature as a third case which has seen extremely rare side effects.